Davis Brian M, Reese Jane S, Lingas Karen, Gerson Stanton L
Division of Hematology/Oncology and the Comprehensive Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106-4937, USA.
J Hematother Stem Cell Res. 2003 Aug;12(4):375-87. doi: 10.1089/152581603322286015.
Optimized hematopoietic gene therapy requires vectors with strong expression in the desired target cell population and the ability to select for the expressing transduced cells. In the context of drug resistance selection of repopulating hematopoietic stem cells in the mouse, we examined tissue expression after transduced marrow transplantation of the drug selection gene, G156A mutant O6-methylguanine-DNA methyltransferase (G156A MGMT). To gain more experience with the rigor of the impact of selection on tissue-specific gene expression, we also asked whether there are expression differences between three different onco-retroviral backbones--MPSV, SF, and MFG. MGMT expression was compared after O6-benzylguanine (BG) and 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) drug selection in vivo. After mice were transplanted with cells transduced with MPSV, MFG, or SF retroviral vectors expressing G156A MGMT and drug treated, nearly complete replacement by transduced progenitors was observed in the marrow. Each backbone supported MGMT expression in all four hematopoietic lineages in vivo indicating that MGMT-mediated selection is indeed robust. Expression in marrow, spleen, and thymus was very similar between the vectors and differences were most likely due to differences in gene copy number per selected cell. In primary and secondary recipients, the highest expression was observed in MFG and this was the vector that transduced at the greatest proviral copy number per cell. These data indicate that strong selection pressure using the MGMT gene to protect primary and secondary repopulating murine stem cells from the toxicity of BCNU. Regardless of the vector backbone used, multiorgan expression was observed without evidence of gene silencing. These data help establish mutant, BG-resistant MGMT as a potent selection gene for stem cell selection in vivo.
优化的造血基因治疗需要在所需靶细胞群体中具有强表达且能够选择表达转导细胞的载体。在小鼠中对重建造血干细胞进行耐药性选择的背景下,我们检测了药物选择基因G156A突变型O6-甲基鸟嘌呤-DNA甲基转移酶(G156A MGMT)转导骨髓移植后的组织表达。为了更多地了解选择对组织特异性基因表达影响的严格程度,我们还研究了三种不同的致癌逆转录病毒骨架——MPSV、SF和MFG之间是否存在表达差异。在体内进行O6-苄基鸟嘌呤(BG)和1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)药物选择后,比较了MGMT的表达。在用表达G156A MGMT的MPSV、MFG或SF逆转录病毒载体转导细胞并进行药物处理后,在小鼠骨髓中观察到转导祖细胞几乎完全替代了原有细胞。每种骨架在体内的所有四个造血谱系中均支持MGMT表达,这表明MGMT介导的选择确实很强。载体之间在骨髓、脾脏和胸腺中的表达非常相似,差异很可能是由于每个选择细胞中基因拷贝数的不同。在初代和二代受体中,MFG中观察到的表达最高,而该载体每个细胞转导的原病毒拷贝数也最多。这些数据表明,使用MGMT基因施加强大的选择压力可保护初代和二代重建造血小鼠干细胞免受BCNU的毒性影响。无论使用何种载体骨架,均观察到多器官表达,且无基因沉默的迹象。这些数据有助于确立突变的、BG耐药的MGMT作为体内干细胞选择的有效选择基因。